期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Heparin is an effective treatment for preventing liver failure after hepatectomy
1
作者 zhi-ying xu Min Peng +3 位作者 Ming-Ming Fan Qi-Fei Zou Yi-Ran Li Dong Jiang 《World Journal of Gastroenterology》 SCIE CAS 2024年第22期2881-2892,共12页
BACKGROUND Posthepatectomy liver failure(PHLF)is one of the most important causes of death following liver resection.Heparin,an established anticoagulant,can protect liver function through a number of mechanisms,and t... BACKGROUND Posthepatectomy liver failure(PHLF)is one of the most important causes of death following liver resection.Heparin,an established anticoagulant,can protect liver function through a number of mechanisms,and thus,prevent liver failure.AIM To look at the safety and efficacy of heparin in preventing hepatic dysfunction after hepatectomy.METHODS The data was extracted from Multiparameter Intelligent Monitoring in Intensive Care III(MIMIC-III)v1.4 pinpointed patients who had undergone hepatectomy for liver cancer,subdividing them into two cohorts:Those who were injected with heparin and those who were not.The statistical evaluations used were unpaired ttests,Mann-Whitney U tests,chi-square tests,and Fisher’s exact tests to assess the effect of heparin administration on PHLF,duration of intensive care unit(ICU)stay,need for mechanical ventilation,use of continuous renal replacement therapy(CRRT),incidence of hypoxemia,development of acute kidney injury,and ICU mortality.Logistic regression was utilized to analyze the factors related to PHLF,with propensity score matching(PSM)aiming to balance the preoperative disparities between the two groups.RESULTS In this study,1388 patients who underwent liver cancer hepatectomy were analyzed.PSM yielded 213 matched pairs from the heparin-treated and control groups.Initial univariate analyses indicated that heparin potentially reduces the risk of PHLF in both matched and unmatched samples.Further analysis in the matched cohorts confirmed a significant association,with heparin reducing the risk of PHLF(odds ratio:0.518;95%confidence interval:0.295-0.910;P=0.022).Additionally,heparin treatment correlated with improved short-term postoperative outcomes such as reduced ICU stay durations,diminished requirements for respiratory support and CRRT,and lower incidences of hypoxemia and ICU mortality.CONCLUSION Liver failure is an important hazard following hepatic surgery.During ICU care heparin administration has been proved to decrease the occurrence of hepatectomy induced liver failure.This indicates that heparin may provide a hopeful option for controlling PHLF. 展开更多
关键词 Liver resection Posthepatectomy liver failure Prophylactic treatment HEPARIN Prognosis of hepatectomy
下载PDF
紫杉醇脂质体治疗进展期胃癌的疗效及安全性研究 被引量:9
2
作者 许晓东 徐志英 谢君 《中国现代医学杂志》 CAS 2020年第5期107-110,共4页
目的探讨紫杉醇(PTX)脂质体联合氟尿嘧啶衍生物(S-1)治疗进展期胃癌的疗效及不良反应。方法选取2016年1月-2018年6月在苏州大学附属张家港医院和张家港市中医医院治疗的进展期胃癌患者97例,根据患者最终选取的治疗方案分为观察组(47例)... 目的探讨紫杉醇(PTX)脂质体联合氟尿嘧啶衍生物(S-1)治疗进展期胃癌的疗效及不良反应。方法选取2016年1月-2018年6月在苏州大学附属张家港医院和张家港市中医医院治疗的进展期胃癌患者97例,根据患者最终选取的治疗方案分为观察组(47例)和对照组(50例)。观察组给予PTX脂质体联合氟尿嘧啶衍生物(S-1)治疗,对照组给予PTX注射液联合S-1治疗,观察两组疗效、中位无进展生存时间和不良反应。结果两组近期疗效比较,差异无统计学意义(P>0.05),两组有效率分别为44.68%和46.00%;两组中位无进展生存时间分别为7个月(95%CI:6.57,7.43)和6个月(95%CI:5.67,6.33),比较差异无统计学意义(P>0.05);观察组骨髓抑制、脱发及关节肌肉疼痛较对照组轻(P<0.05);观察组和对照组恶心呕吐、肝功能受损及外周神经不良反应比较,差异无统计学意义(P>0.05)。结论PTX脂质体联合S-1治疗进展期胃癌有一定疗效,具有不良反应轻的优点。 展开更多
关键词 胃肿瘤 紫杉醇脂质体 氟尿嘧啶衍生物
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部